Clinical Trials List
Protocol NumberKMUH-IIT-109-1-13
2020-06-15 - 2022-03-20
Phase II
Recruiting1
ICD-10L80
Vitiligo
ICD-9709.01
Vitiligo
A study assessing the safety and efficacy of combining low-dose Tofacitinib with 308 nm excimer light for treating vitiligo: Establishing a safe, cost-effective, and efficient new paradigm
-
Trial Applicant
-
Sponsor
KMUH/MHW
-
Trial scale
Taiwan Single Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Ting-Ting Yang Division of Dermatology
- Sheng Yiao Lin Division of Dermatology
- 陳盈君 Division of Dermatology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
vitiligo
Objectives
A
Test Drug
Tofacitinib
Active Ingredient
tofacitinib
Dosage Form
Dosage
5mg
Endpoints
A
Inclution Criteria
A
Exclusion Criteria
A
The Estimated Number of Participants
-
Taiwan
026 participants
-
Global
0 participants
